Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells

International Journal of Molecular Medicine

Volumn 33, Issue 1, 2014, Pages 151-159

  Zhang, Pei ^a   Liu, Hao ^a   Xia, Fei ^a   Zhang, Qian Wen ^a   Zhang, Yuan Yuan ^a   Zhao, Qing ^a   Chao, Zhen Hua ^a   Jiang, Zhi Wen ^a   Jiang, Chen Chen ^a,b  

^a BENGBU MEDICAL COLLEGE   (China)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Chemoresistance; Epithelial mesenchymal transition; Invasion; Migration; Nasopharyngeal carcinoma

Indexed keywords

BETA CATENIN; CISPLATIN; FIBRONECTIN; GELATINASE B; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN;

ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CELL VIABILITY ASSAY; DOWN REGULATION; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; NASOPHARYNX CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PSEUDOPODIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

BETA CATENIN; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; HOMEODOMAIN PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 9; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; TRANSCRIPTION FACTORS; UP-REGULATION; VIMENTIN;

EID: 84892745892     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1538     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Chen QY, Wen YF, Guo L, et al: Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103: 1761-1770, 2011.
3. Brabec V and Kasparkova J: Modi fications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8: 131-146, 2005.
4. Li Q, Kawamura K, Yamanaka M, et al: Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19: 218-228, 2012.
5. Wang L, Xiang S, Williams KA, et al: Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 7: e44265, 2012.
6. Shellard SA, Fichtinger-Schepman AM, Lazo JS and Hill BT: Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4: 491-500, 1993.
7. Torigoe T, Izumi H, Ishiguchi H, et al: Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5: 15-27, 2005.
8. Cheung HW, Jin DY, Ling MT, et al: Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 65: 1450-1458, 2005.
9. Hugo H, Ackland ML, Blick T, et al: Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383, 2007.
10. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
11. Kim MR, Choi HK, Cho KB, Kim HS and Kang KW: Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 100: 1834-1841, 2009.
12. Kajiyama H, Shibata K, Terauchi M, et al: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283, 2007.
13. Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
14. Gu MF, Liu LZ, He LJ, et al: Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma. Int J Cancer 132: 215-223, 2013.
15. Xie SM, Fang WY, Liu TF, Yao KT and Zhong XY: Association of ABCC2 and CDDP-resistance in two sublines resistant to CDDP derived from a human nasopharyngeal carcinoma cell line. J Oncol 2010: 915046, 2010.
16. Wong RS and Cheong SK: Leukaemic stem cells: drug resistance, metastasis and therapeutic implications. Malays J Pathol 34: 77-88, 2012.
17. Valastyan S and Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292, 2011.
18. Danila DC, Heller G, Gignac GA, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053-7058, 2007.
19. Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L and Clynes M: Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 37: 1041-1052, 2001.
20. Haga A, Nagase H, Kito H and Sato T: Invasive properties of cadmium-resistant human fibrosarcoma HT-1080 cells. Cancer Biochem Biophys 15: 275-284, 1997.
21. Wang Z, Li Y, Ahmad A, et al: Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118, 2010.
22. Haslehurst AM, Koti M, Dharsee M, et al: EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12: 91, 2012.
23. Moustakas A and Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520, 2007.
24. Pai MH, Kuo YH, Chiang EP and Tang FY: S-Allylcysteine inhibits tumour progression and the epithelial-mesenchymal transition in a mouse xenograft model of oral cancer. Br J Nutr 108: 28-38, 2012.
25. Jing Y, Han Z, Liu Y, et al: Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One 7: e43272, 2012.
26. Comijn J, Berx G, Vermassen P, et al: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7: 1267-1278, 2001.
27. Wang X, Ling MT, Guan XY, et al: Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23: 474-482, 2004.
28. Rudin CM, Yang Z, Schumaker LM, et al: Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63: 312-318, 2003.
29. Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64: 706-721, 2012.
30. Barr MP, Gray SG, Hoffmann AC, et al: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8: e54193, 2013.